Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
Latest Information Update: 27 Feb 2026
At a glance
- Drugs Levacetylleucine (Primary)
- Indications Ataxia telangiectasia
- Focus Expanded access; Therapeutic Use
- Sponsors IntraBio
Most Recent Events
- 24 Feb 2026 Status changed from suspended to recruiting.
- 06 Feb 2026 New trial record